Roche announces the release of its newest artificial intelligence based digital pathology algorithms to aid pathologists in evaluation of breast cancer markers, Ki-67, ER and PR

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the research use only (RUO) launch of three new automated digital pathology algorithms, uPath Ki-67 (30-9), uPath ER (SP1) and uPath PR (1E2) image analysis for breast cancer, which are important biomarkers for breast cancer patients. Breast cancer is the second most common cancer in the world with an estimated 2.3 million new cases in 2020¹ and is the most common cancer in women globally¹,². These new algorithms complete the Roche digital pathology breast panel of image analysis algorithms. This includes a whole slide analysis workflow with automated pre-computing of the slide image prior to pathologist assessment, and a clear visual overlay highlighting tumour cells with and without nuclear staining. Intended for use with Roche's high medical value assays and slides stained on a BenchMark ULTRA instrument using ultraView DAB detection kit, the uPath Ki-67 (30-9) image analysis, uPath ER (SP1) image analysis and uPath PR (1E2) image analysis algorithms are ready-to-use and integrated within Roche's uPath enterprise software and NAVIFY Digital Pathology, the cloud version of uPath.